Finance Watch: Frontier Raises $80m For Differentiated KRAS G12C Program
Phase I/II Trial Of FMC-376 Enrolled First Patient
Private Company Edition: With its lead program in the clinic, Frontier’s $80m series C round will fund trials for additional programs. Also, ORI raises $260m for second fund, Earlybird closed a €173m ($187.1m) fund, Areteia’s series A grew to $425m and Sudo’s series B increased to $147m.
